However, the evidence reported in this review suggest that candidate mAbs to be possibly used in antiviral passive immunization approaches, or to be elicited by future vaccine strategies, have not only to be highly cross-neutralizing molecules [141,142], but also tailored molecules whose activity is not influenced by possible interfering Abs produced in the course of infection. Here, DDX41 is linked to infection.